Kaposi's sarcoma drug trial halted early – what we know
NCT ID NCT01412515
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested the drug everolimus in 11 people with classic or endemic Kaposi's sarcoma, a rare skin cancer linked to a virus. The goal was to see if the drug could shrink tumors after 6 months. The study was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- everolimus
- What this could lead to
- If successful, this could point toward a new oral treatment option for Kaposi's sarcoma that does not require chemotherapy.
- What could go wrong
- This was a small, early-phase trial that was terminated, so results are limited. The drug may not work for everyone and can cause side effects like mouth sores or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC KAPOSI'S SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Saint Louis
Paris, 75010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail targets rare, aggressive cancer
- Scientists seek tissue samples to unlock HIV-Cancer mysteries
- New drug shows promise in blocking kaposi sarcoma growth
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
- Scientists probe blood vessel role in skin disorders